Skip to main content

EGLN1/PHD2 Antibody (2445B) - BSA Free

Novus Biologicals, part of Bio-Techne | Catalog # NBP2-76810

Recombinant Monoclonal Antibody.
Novus Biologicals, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
Loading...
NBP2-76810
NBP2-76810SS

Key Product Details

Species Reactivity

Human

Applications

Flow (Intracellular), Flow Cytometry, Immunocytochemistry/ Immunofluorescence, Immunohistochemistry, Immunohistochemistry-Paraffin, Western Blot

Label

Unconjugated

Antibody Source

Recombinant Monoclonal Rabbit IgG Clone # 2445B

Format

BSA Free

Concentration

1.0 mg/ml

Product Specifications

Immunogen

This EGLN1/PHD2 antibody was developed against a partial synthetic peptide from the N-terminal portion of the human EGLN1/PHD2 protein.

Clonality

Monoclonal

Host

Rabbit

Isotype

IgG

Theoretical MW

46 kDa.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.

Scientific Data Images for EGLN1/PHD2 Antibody (2445B) - BSA Free

Immunohistochemistry-Paraffin: EGLN1/PHD2 Antibody (2445B) - BSA Free [NBP2-76810]

Immunohistochemistry-Paraffin: EGLN1/PHD2 Antibody (2445B) - BSA Free [NBP2-76810]

Immunohistochemistry-Paraffin: EGLN1/PHD2 Antibody (2445B) [NBP2-76810] - EGLN1/PHD2 was detected in immersion fixed paraffin-embedded sections of human kidney using Rabbit Anti-EGLN1/PHD2 Monoclonal Antibody (Catalog #NBP2-76810) at 3 ug/mL for 1 hour at room temperature followed by incubation with the Anti-Rabbit IgG VisUCyt(TM) HRP Polymer Antibody (Catalog # VC003). Before incubation with the primary antibody, tissue was subjected to heat-induced epitope retrieval using Antigen Retrieval Reagent-Basic (Catalog # CTS013). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue). Specific staining was localized to cell cytoplasm and nuclei.
Western Blot: EGLN1/PHD2 Antibody (2445B)BSA Free [NBP2-76810]

Western Blot: EGLN1/PHD2 Antibody (2445B)BSA Free [NBP2-76810]

Western Blot: EGLN1/PHD2 Antibody (2445B) [NBP2-76810] - Total protein from human HeLa, THP-1 and U87 cell lines was separated on a 12% gel by SDS-PAGE, transferred to PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 2.0 ug/mL anti-PHD2 antibody in block buffer and detected with an anti-rabbit HRP secondary antibody using West Pico PLUS chemiluminescence detection reagent.
Immunocytochemistry/ Immunofluorescence: EGLN1/PHD2 Antibody (2445B) - BSA Free [NBP2-76810]

Immunocytochemistry/ Immunofluorescence: EGLN1/PHD2 Antibody (2445B) - BSA Free [NBP2-76810]

Immunocytochemistry/Immunofluorescence: EGLN1/PHD2 Antibody (2445B) [NBP2-76810] - EGLN1/PHD2 was detected in immersion fixed WM-115 human malignant melanoma cell line using Rabbit Anti-EGLN1/PHD2 Monoclonal Antibody (Catalog # NBP2-76810) at 3 ug/mL for 3 hours at room temperature. Cells were stained using the NorthernLight(TM) 557-conjugated Anti-Rabbit IgG secondary antibody (red; Catalog # NL004) and counterstained with DAPI (blue). Specific staining was localized to cell cytoplasm and nuclei.

Applications for EGLN1/PHD2 Antibody (2445B) - BSA Free

Application
Recommended Usage

Flow (Intracellular)

0.25 ug

Flow Cytometry

0.25 ug

Immunocytochemistry/ Immunofluorescence

5 - 20 ug/mL

Immunohistochemistry

5 - 20 ug/mL

Immunohistochemistry-Paraffin

5 - 20 ug/mL

Western Blot

1 - 2 ug/mL

Formulation, Preparation, and Storage

Purification

Protein A or G purified

Formulation

PBS

Format

BSA Free

Preservative

0.02% Sodium Azide

Concentration

1.0 mg/ml

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.

Background: EGLN1/PHD2

PHD2 (Prolyl Hydroxylase Domain-containing protein 2) belongs to the Prolyl-4-hydroxylase domain (PHD) family of proteins and is encoded by the Egl-9 Family Hypoxia Inducible Factor 1 (EGLN1) gene (1). Human EGLN1/PHD2 is a ubiquitously expressed enzyme that is 426 amino acids (aa) long with a theoretical molecular weight of ~46 kDa. Structurally PHD2 contains a nuclear export signal (NES, aa 6-20), an N-terminal MYND zinc finger domain (aa 21-58), and a C-terminal catalytic domain (aa 291-392) (2, 3). Functionally, PHD2 serves as an oxygen sensor and is responsible for post-translational modification of Hypoxia-inducible factor alpha (HIF-1alpha), a component of a transcriptional complex involved in oxygen homeostasis (1-3). During normoxia, PHD2 is responsible for oxygen-dependent hydroxylation of HIF-1alpha proline residue 402, 564, or both (3). The hydroxylation event promotes the binding of von Hippel-Lindau protein (VHL) and targets HIF1-alpha for ubiquitination and degradation (4, 5).

EGLN1/PHD2 has been implicated in several critical processes including erythropoiesis, angiogenesis, and metabolism as well as various pathologies such as cancer (2, 5, 6). Studies in mice have found that somatic deletion of PHD2 resulted in higher vascular endothelial growth factor A (VEGF-A) levels, increased blood vessel formation, and more erythropoietin (EPO), leading to severe polycythemia or erythrocytosis (high red blood cell (RBC) volume) (6). Another study revealed that specific point mutations in EGLN1/PHD2 led to elevated EPO and RBC mass associated with hemorrhages and strokes (6). Accordingly, given the known role of PHD2 in inhibition of EPO production, PHD2 inhibitors are being studied as a potential therapeutic for anemia (6). Additionally, dysregulation in EGLN1, and specifically the PHD2-VHL-HIF-1alpha pathway, has been associated with the development of pheochromocytomas (PCC) and sympathetic paragangliomas (PGL), which are rare neuroendocrine tumors (2). Besides pathological features, EGLN1/PHD2 may also be important for high altitude adaptation as two coding sequence variants in PHD2 are prevalent in the Tibetan population but is very rare in people at lower altitudes (2).

Alternate names for EGLN1/PHD2 include HIF Prolyl Hydroxylase 2, PH2, Prolyl hydroxylase domain containing protein 2, HIF2PH2, HIF-Prolyl hydroxylase 2, egl nine homolog 1, and C1orf12.

References

1. Amorim-Pires, D., Peixoto, J., & Lima, J. (2016). Hypoxia Pathway Mutations in Pheochromocytomas and Paragangliomas. Cytogenetic and genome research. https://doi.org/10.1159/000457479

2. Gardie, B., Percy, M. J., Hoogewijs, D., Chowdhury, R., Bento, C., Arsenault, P. R., Richard, S., Almeida, H., Ewing, J., Lambert, F., McMullin, M. F., Schofield, C. J., & Lee, F. S. (2014). The role of PHD2 mutations in the pathogenesis of erythrocytosis. Hypoxia (Auckland, N.Z.). https://doi.org/10.2147/HP.S54455

3. Minervini, G., Quaglia, F., & Tosatto, S. C. (2015). Insights into the proline hydroxylase (PHD) family, molecular evolution and its impact on human health. Biochimie. https://doi.org/10.1016/j.biochi.2015.07.009

4. Semenza G. L. (2007). Hypoxia-inducible factor 1 (HIF-1) pathway. Science's STKE : signal transduction knowledge environment. https://doi.org/10.1126/stke.4072007cm8

5. Chan, D. A., & Giaccia, A. J. (2010). PHD2 in tumour angiogenesis. British journal of cancer. https://doi.org/10.1038/sj.bjc.6605682

6. Meneses, A. M., & Wielockx, B. (2016). PHD2: from hypoxia regulation to disease progression. Hypoxia (Auckland, N.Z.). https://doi.org/10.2147/HP.S53576

Long Name

Egl Nine Homolog 1/Prolyl Hydroxylase Domain-containing Protein 2

Alternate Names

C1orf12, HIFPH2, HPH2, PHD2, SM20, ZMYND6

Gene Symbol

EGLN1

Additional EGLN1/PHD2 Products

Product Documents for EGLN1/PHD2 Antibody (2445B) - BSA Free

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Product Specific Notices for EGLN1/PHD2 Antibody (2445B) - BSA Free

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Loading...
Loading...
Loading...
Loading...
Loading...
Loading...